Evotec to Screen Compounds for Genentech | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Evotec said today that it will screen small molecule compounds for drug developer Genentech under a new collaborative agreement.

Under the multi-year alliance, Evotec will use its disease knowledgebase and drug discovery platform to test small molecule candidates for the Roche subsidiary. The research will include assay development, high-throughput screening, structural biology, and medicinal chemistry services, Hamburg-based Evotec said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.